Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
89 hedge funds and large institutions have $385M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 12 closing their positions.
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
16% more funds holding
Funds holding: 77 → 89 (+12)
5% more capital invested
Capital invested by funds: $366M → $385M (+$18.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less call options, than puts
Call options by funds: $4K | Put options by funds: $893K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$19.8M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$17.6M |
| 3 |
BlackRock
New York
|
+$17M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$14M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.34M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.09M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.05M |
| 4 |
Janus Henderson Group
London,
|
-$2.7M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.58M |
KDNY Hedge Fund Activity: Q2 2021 in Review
89 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2021, worth a combined $385M — up 5.1% from $366M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KDNY positions and 12 closed out — a net gain of 12 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $19.8M. The largest seller was Vivo Capital, cutting an estimated $5.34M.
- 89 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2021, up from 77 in Q1 2021.
- Funds reported $385M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2021, up 5.1% quarter-over-quarter.
- 24 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2021 and 12 closed out, a net change of +12 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2021 was Armistice Capital, an estimated $19.8M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2021 was Vivo Capital, an estimated $5.34M sold.
Based on aggregated 13F filings for Q2 2021.